Table 1

From: Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function

 

N

Pre-ablation M (P25, P75)

Post-ablation M (P25, P75)

Z

p

E 2

 3 months

142

364.40 (212.94, 573.89)

397.63 (255.00, 533.30)

−0.084a

0.933

 6 months

49

345.56 (217.93, 651.19)

350.00 (262.93, 600.92)

−0.016a

0.987

 9 months

33

304.25 (204.72, 431.72)

400.88 (273.41,671.84)

−1.616a

0.106

 12 months

39

326.32 (205.60, 573.01)

350.13 (244.22, 480.38)

−0.080a

0.936

FSH

 3 months

142

4.98 (3.44, 6.98)

4.89 (3.13, 6.49)

−0.594a

0.552

 6 months

49

5.71 (3.70, 6.99)

5.14 (3.60, 6.68)

−1.048b

0.295

 9 months

33

5.72 (3.73, 7.15)

4.59 (3.30, 6.84)

−0.817b

0.414

 12 months

39

5.37 (3.65, 6.23)

5.59 (2.90, 8.24)

−0.305b

0.76

PRL

 3 months

142

21.35 (14.89, 32.27)

8.59 (6.65, 11.94)

−7.162a

 < 0.001

 6 months

49

23.69 (16.05,32.40)

8.00 (6.22, 11.65)

−4.914a

 < 0.001

 9 months

33

23.69 (13.35, 30.35)

10.01 (7.38, 13.04)

−3.736b

 < 0.001

 12 months

39

21.33 (13.55, 35.41)

9.53 (7.15, 15.38)

−3.582a

 < 0.001

  1. Serum hormone outcomes before and after PMWA.
  2. M median; P:percentile.
  3. Z: Z-score.
  4. p: significance probability.
  5. aBased on the positive ranks.
  6. bBased on the negative ranks.